Lidocaine Sans Conservateur Aguettant (Lidocaine Hydrochloride Monohydrate)

Lidocaine acts by blocking voltage‑gated sodium channels on neuronal membranes. This blockade prevents the influx of sodium ions needed for depolarization, thereby inhibiting the initiation and propagation of nerve impulses. The result is a temporary loss of sensory perception in the area where the drug is administered.

The dose of Lidocaine Sans Conservateur Aguettant is determined by the prescribing clinician based on the procedure, route of administration, patient weight, age and overall health. Healthcare professionals calculate the appropriate volume and concentration to stay within safe maximum dose limits for each specific indication.

Safety data for lidocaine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any necessary import documentation.

Lidocaine has a faster onset of action (typically 1–3 minutes) but a shorter duration (1–2 hours) compared with bupivacaine, which takes longer to act (5–10 minutes) but can provide analgesia for up to 6–8 hours. Choice between them depends on the required speed of onset, duration of the procedure and the patient’s cardiovascular risk profile.

Lidocaine Sans Conservateur Aguettant should be stored at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from direct light and moisture, and avoid freezing. Inspect the solution for particulate matter or discoloration before use.

The product is administered by a qualified healthcare professional via injection. Depending on the clinical need, it can be given epidurally, infiltrated into soft tissue, or injected intramuscularly. Proper aseptic technique and accurate dosing are essential to achieve effective anesthesia and minimize toxicity.

The most serious risks include systemic toxicity leading to central nervous system depression, seizures, respiratory arrest, and cardiac arrhythmias such as ventricular tachycardia or heart block. Rarely, severe allergic reactions or methemoglobinemia may occur. Immediate medical attention is required if any of these symptoms develop.

Patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics should avoid this product. It is also contraindicated in individuals with severe heart block, uncontrolled epilepsy, or those who have received excessive cumulative doses of local anesthetics within a short period.